Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity (original) (raw)

• Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917 (2010).
  Article CAS PubMed Google Scholar
• Dudek, A. M., Grotenhuis, A. J., Vermeulen, S. H., Kiemeney, L. A. & Verhaegh, G. W. Urinary bladder cancer susceptibility carkers. What do we know about functional mechanisms? Int. J. Mol. Sci. 14, 12346–12366 (2013). This is an excellent review of findings of genome-wide association studies in bladder cancer and possible functional mechanisms.
  Article CAS PubMed PubMed Central Google Scholar
• Union Internationale Contre le Cancer (UICC) in TNM Classification of Malignant Tumors 7th edn 262–265 (UICC, 2009).
• Eble, J. N., Sauter, G., Epstein, J. I. & Sesterhenn, I. A. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs (IARC Press Lyon, 2004).
  Google Scholar
• World Health Organization. Histological Typing of Urinary Bladder Tumours. (WHO, 1973).
• Prout, G. R. Jr., Barton, B. A., Griffin, P. P. & Friedell, G. H. Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J. Urol. 148, 1413–1419 (1992).
  Article PubMed Google Scholar
• Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466–477 (2006).
  Article PubMed Google Scholar
• Soloway, M. S. Bladder cancer: lack of progress in bladder cancer — what are the obstacles? Nature Rev. Urol. 10, 5–6 (2013).
  Article Google Scholar
• Morrison, C. D. et al. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc. Natl Acad. Sci. USA 111, E672–E681 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Bentley, J., Diggle, C. P., Harnden, P., Knowles, M. A. & Kiltie, A. E. DNA double strand break repair in human bladder cancer is error prone and involves microhomology-associated end-joining. Nucleic Acids Res. 32, 5249–5259 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Balbas-Martinez, C. et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nature Genet. 45, 1464–1469 (2013).
  Article CAS PubMed Google Scholar
• Solomon, D. A. et al. Frequent truncating mutations of STAG2 in bladder cancer. Nature Genet. 45, 1428–1430 (2013).
  Article CAS PubMed Google Scholar
• Taylor, C., Platt, F., Hurst, C., Thygensen, H. & Knowles, M. A. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumor grade and stage and inversely related to chromosomal copy number changes. Hum. Mol. Genet. 23, 1964–1974 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Solomon, D. A. et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333, 1039–1043 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Baranello, L., Kouzine, F. & Levens, D. CTCF and cohesin cooperate to organize the 3D structure of the mammalian genome. Proc. Natl Acad. Sci. USA 111, 889–890 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Kong, X. et al. Distinct functions of human cohesin-SA1 and cohesin-SA2 in double-strand break repair. Mol. Cell. Biol. 34, 685–698 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Guo, G. et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nature Genet. 45, 1459–1463 (2013).
  Article CAS PubMed Google Scholar
• Cairns, P. et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265, 415–417 (1994).
  Article CAS PubMed Google Scholar
• Williamson, M. P., Elder, P. A., Shaw, M. E., Devlin, J. & Knowles, M. A. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum. Mol. Genet. 4, 1569–1577 (1995).
  Article CAS PubMed Google Scholar
• Aboulkassim, T. O., LaRue, H., Lemieux, P., Rousseau, F. & Fradet, Y. Alteration of the PATCHED locus in superficial bladder cancer. Oncogene 22, 2967–2971 (2003).
  Article CAS PubMed Google Scholar
• McGarvey, T. W., Maruta, Y., Tomaszewski, J. E., Linnenbach, A. J. & Malkowicz, S. B. PTCH gene mutations in invasive transitional cell carcinoma of the bladder. Oncogene 17, 1167–1172 (1998).
  Article CAS PubMed Google Scholar
• Habuchi, T., Luscombe, M., Elder, P. A. & Knowles, M. A. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32–q33. Genomics 48, 277–288 (1998).
  Article CAS PubMed Google Scholar
• Nishiyama, H., Hornigold, N., Davies, A. & Knowles, M. A. A sequence-ready 840-kb PAC contig spanning the candidate tumor suppressor locus DBC1 on human chromosome 9q32-q33. Genomics 59, 335–338 (1999).
  Article CAS PubMed Google Scholar
• Platt, F. M. et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin. Cancer Res. 15, 6008–6017 (2009).
  Article CAS PubMed Google Scholar
• Sjodahl, G. et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS ONE 6, e18583 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ploussard, G. et al. Prognostic value of loss of heterozygosity at chromosome 9p in non-muscle-invasive bladder cancer. Urology 76, e513–e518 (2010).
  Article Google Scholar
• Kruger, S., Mahnken, A., Kausch, I. & Feller, A. C. p16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur. Urol. 47, 463–467 (2005).
  Article CAS PubMed Google Scholar
• Bartoletti, R. et al. Loss of p16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J. Surg. Res. 143, 422–427 (2007).
  Article CAS PubMed Google Scholar
• Carnero, A., Hudson, J. D., Price, C. M. & Beach, D. H. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nature Cell Biol. 2, 148–155 (2000).
  Article CAS PubMed Google Scholar
• Serrano, M. The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis 21, 865–869 (2000).
  Article CAS PubMed Google Scholar
• Rebouissou, S. et al. CDKN2A homozygous deletion is associated with muscle invasion in _FGFR3_-mutated urothelial bladder carcinoma. J. Pathol. 227, 315–324 (2012). This study suggests that deletion of p16 makes a critical contribution to progression of NMIBCs. Subsequent genome sequencing studies (such as reference 37) define a subgroup of MIBCs with this profile.
  Article CAS PubMed Google Scholar
• Le Frere-Belda, M. A. et al. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status. Hum. Pathol. 35, 817–824 (2004).
  Article CAS PubMed Google Scholar
• Benedict, W. F. et al. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 18, 1197–1203 (1999).
  Article CAS PubMed Google Scholar
• Shariat, S. F. et al. p53, 21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 22, 1014–1024 (2004).
  Article CAS PubMed Google Scholar
• Rampias, T. et al. A new tumor suppressor role for the Notch pathway in bladder cancer. Nature Med. 20, 1199–1205 (2014).
  Article CAS PubMed Google Scholar
• Gui, Y. et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature Genet. 43, 875–878 (2011). This was the first major whole-exome sequencing study of bladder cancer, which identified frequent mutation of chromatin modifier genes.
  Article CAS PubMed Google Scholar
• The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014). This is the most comprehensive analysis of MIBC so far, including whole-exome sequencing, RNA sequencing and profiling of microRNAs, methylation and protein expression. See also references 173 and 194.
• Hoglund, M. The bladder cancer genome; chromosomal changes as prognostic makers, opportunities, and obstacles. Urol. Oncol. 30, 533–540 (2012).
  Article CAS PubMed Google Scholar
• Knowles, M. A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27, 361–373 (2006).
  Article CAS PubMed Google Scholar
• Knowles, M. A. Bladder cancer subtypes defined by genomic alterations. Scand. J. Urol. Nephrol. 218, S116–S130 (2008).
  Article Google Scholar
• Lindgren, D. et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE 7, e38863 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Nishiyama, N. et al. Copy number alterations in urothelial carcinomas: their clinicopathological significance and correlation with DNA methylation alterations. Carcinogenesis 32, 462–469 (2011).
  Article CAS PubMed Google Scholar
• Hurst, C. D., Platt, F. M., Taylor, C. F. & Knowles, M. A. Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin. Cancer Res. 18, 5865–5877 (2012). This study uses a genomic approach to bladder tumour subclassification. It describes potential subclasses of the 'gold-standard' stage and grade groups based on DNA copy number and mutation.
  Article CAS PubMed PubMed Central Google Scholar
• Nord, H. et al. Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Int. J. Cancer 126, 1390–1402 (2010).
  CAS PubMed Google Scholar
• Eriksson, P. et al. Detailed analysis of focal chromosome arm 1q and 6p amplifications in urothelial carcinoma reveals complex genomic events on 1q, and as a possible auxiliary target on 6p. PLoS ONE 8, e67222 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Williams, S. V., Hurst, C. D. & Knowles, M. A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 22, 795–803 (2012). This study was the first to identify oncogenic FGFR3 fusions in bladder cancer. Importantly, cell lines with FGFR3 fusions were those previously reported to show high sensitivity to FGFR-targeted agents.
  Article CAS PubMed PubMed Central Google Scholar
• Nordentoft, I. et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep. 7, 1649–1663 (2014).
  Article CAS PubMed Google Scholar
• Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nature Genet. 45, 970–976 (2013).
  Article CAS PubMed Google Scholar
• Burns, M. B., Temiz, N. A. & Harris, R. S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nature Genet. 45, 977–983 (2013).
  Article CAS PubMed Google Scholar
• Cappellen, D. et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genet. 23, 18–20 (1999). This study was the first to describe FGFR3 mutations in bladder cancer.
  Article CAS PubMed Google Scholar
• Zieger, K. et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin. Cancer Res. 11, 7709–7719 (2005).
  Article CAS PubMed Google Scholar
• Hernandez, S. et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin. Oncol. 24, 3664–3671 (2006).
  Article CAS PubMed Google Scholar
• Kompier, L. C. et al. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J. Pathol. 218, 104–112 (2009).
  Article CAS PubMed Google Scholar
• Barbisan, F. et al. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer 112, 636–644 (2008).
  Article PubMed Google Scholar
• Burger, M. et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur. Urol. 54, 835–844 (2007).
  Article PubMed Google Scholar
• van Rhijn, B. W. et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J. Urol. 187, 310–314 (2012).
  Article CAS PubMed Google Scholar
• Billerey, C. et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158, 1955–1959 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Kimura, T. et al. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 92, 2555–2561 (2001).
  Article CAS PubMed Google Scholar
• Tomlinson, D. C., Baldo, O., Harnden, P. & Knowles, M. A. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 213, 91–98 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• di Martino, E., L' Hôte, C. G., Kennedy, W., Tomlinson, D. C. & Knowles, M. A. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene 28, 4306–4316 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Kiemeney, L. A. et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nature Genet. 42, 425–419 (2010).
  Article CAS Google Scholar
• Tomlinson, D. C., L'Hôte, C. G., Kennedy, W., Pitt, E. & Knowles, M. A. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res. 65, 10441–10449 (2005).
  Article CAS PubMed Google Scholar
• Zhang, X. et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 281, 15694–15700 (2006).
  Article CAS PubMed Google Scholar
• Catto, J. W. et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 69, 8472–8481 (2009). This study describes widespread alterations in microRNA expression in bladder cancer. A particularly interesting finding in low-grade tumours is loss of miR-99a and miR-100, which leads to upregulation of FGFR3.
  Article CAS PubMed PubMed Central Google Scholar
• Tomlinson, D. C., Lamont, F. R., Shnyder, S. D. & Knowles, M. A. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res. 69, 4613–4620 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Tomlinson, D. C. & Knowles, M. A. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am. J. Pathol. 177, 2379–2386 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Tomlinson, D. C., Baxter, E. W., Loadman, P. M., Hull, M. A. & Knowles, M. A. FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms. PLoS ONE 7, e38972 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Cheng, T. et al. Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. PLoS ONE 8, e57284 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Kassouf, W. et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J. Urol. 179, 353–358 (2008).
  Article PubMed Google Scholar
• Jimenez, R. E. et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res. 7, 2440–2447 (2001).
  CAS PubMed Google Scholar
• Kruger, S. et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int. J. Cancer 102, 514–518 (2002).
  Article CAS PubMed Google Scholar
• Forster, J. A., Paul, A. B., Harnden, P. & Knowles, M. A. Expression of NRG1 and its receptors in human bladder cancer. Br. J. Cancer 104, 1135–1143 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Fleischmann, A., Rotzer, D., Seiler, R., Studer, U. E. & Thalmann, G. N. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur. Urol. 60, 350–357 (2011).
  Article CAS PubMed Google Scholar
• Cheng, H. L. et al. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br. J. Cancer 92, 1906–1914 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Cheng, H. L. et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J. Clin. Oncol. 20, 1544–1550 (2002).
  Article CAS PubMed Google Scholar
• Sanchez-Carbayo, M., Socci, N. D., Lozano, J. J., Haab, B. B. & Cordon-Cardo, C. Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol. 168, 93–103 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Juanpere, N. et al. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Hum. Pathol. 43, 1573–1582 (2012).
  Article CAS PubMed Google Scholar
• López-Knowles, E. et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 66, 7401–7404 (2006).
  Article PubMed Google Scholar
• Kompier, L. C. et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE 5, e13821 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, L. & Vogt, P. K. Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl Acad. Sci. USA 105, 2652–2657 (2008).
  Article PubMed PubMed Central Google Scholar
• Ross, R. L., Askham, J. M. & Knowles, M. A. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. Oncogene 32, 768–776 (2012).
  Article CAS PubMed Google Scholar
• Aveyard, J. S., Skilleter, A., Habuchi, T. & Knowles, M. A. Somatic mutation of PTEN in bladder carcinoma. Br. J. Cancer 80, 904–908 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Cappellen, D., Gil Diez de Medina, S., Chopin, D., Thiery, J. P. & Radvanyi, F. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive. Oncogene 14, 3059–3066 (1997).
  Article CAS PubMed Google Scholar
• Kagan, J. et al. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene 16, 909–913 (1998).
  Article CAS PubMed Google Scholar
• Puzio-Kuter, A. M. et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 23, 675–680 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Gildea, J. J. et al. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene 23, 6788–6797 (2004).
  Article CAS PubMed Google Scholar
• Jebar, A. H. et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24, 5218–5225 (2005).
  Article CAS PubMed Google Scholar
• Karlou, M. et al. Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations. Pathol. 41, 327–334 (2009).
  Article CAS Google Scholar
• Swiatkowski, S. et al. Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp. Cell Res. 282, 48–57 (2003).
  Article CAS PubMed Google Scholar
• Kastritis, E. et al. Somatic mutations of adenomatous polyposis coli gene and nuclear β-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. Int. J. Cancer 124, 103–108 (2009).
  Article CAS PubMed Google Scholar
• Zhu, X., Kanai, Y., Saito, A., Kondo, Y. & Hirohashi, S. Aberrant expression of β-catenin and mutation of exon 3 of the β-catenin gene in renal and urothelial carcinomas. Pathol. Int. 50, 945–952 (2000).
  Article CAS PubMed Google Scholar
• Kashibuchi, K. et al. The prognostic value of E-cadherin, α-, β- and γ-catenin in bladder cancer patients who underwent radical cystectomy. Int. J. Urol. 14, 789–794 (2007).
  Article CAS PubMed Google Scholar
• Baumgart, E. et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin. Cancer Res. 13, 1685–1694 (2007).
  Article CAS PubMed Google Scholar
• Marsit, C. J. et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res. 65, 7081–7085 (2005).
  Article CAS PubMed Google Scholar
• Urakami, S. et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/β-catenin signaling pathway. Clin. Cancer Res. 12, 383–391 (2006).
  Article CAS PubMed Google Scholar
• Ahmad, I. et al. β-catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 30, 178–189 (2011).
  Article CAS PubMed Google Scholar
• Lin, C. et al. Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium. Cancer Res. 73, 5914–5925 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Ahmad, I. et al. Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis. Cell Death Dis. 2, e124 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Shin, K. et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 472, 110–114 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Shin, K. et al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nature Cell Biol. 16, 469–478 (2014).
  Article CAS PubMed Google Scholar
• Shin, K. et al. Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell 26, 521–533 (2014). Using the BBN-induced invasive bladder cancer mouse model, this study provides evidence for a tumour suppressor role for hedgehog signalling from urothelium to stroma that in turn influences urothelial cell differentiation. BMP4 and BMP5 were among the SHH-induced stromal factors that stimulated urothelial differentiation. Importantly, pharmacological activation of the BMP pathway was shown to block tumour progression in this system.
  Article CAS PubMed PubMed Central Google Scholar
• Thievessen, I., Wolter, M., Prior, A., Seifert, H. H. & Schulz, W. A. Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines. J. Cell. Physiol. 203, 372–377 (2005).
  Article CAS PubMed Google Scholar
• Mitra, A. P., Hansel, D. E. & Cote, R. J. Prognostic value of cell-cycle regulation biomarkers in bladder cancer. Semin. Oncol. 39, 524–533 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Hurst, C. D., Tomlinson, D. C., Williams, S. V., Platt, F. M. & Knowles, M. A. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene 27, 2716–2727 (2008).
  Article CAS PubMed Google Scholar
• Proctor, A., Coombs, L., Cairns, J. & Knowles, M. Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene 6, 789–795 (1991).
  CAS PubMed Google Scholar
• Lopez-Beltran, A. et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1–S modulators (p53, 21Waf1, 27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am. J. Clin. Pathol. 122, 444–452 (2004).
  Article PubMed Google Scholar
• Kim, W. J. & Kim, Y. J. Epigenetic biomarkers in urothelial bladder cancer. Expert Rev. Mol. Diagn. 9, 259–269 (2009).
  Article CAS PubMed Google Scholar
• Dudziec, E., Goepel, J. R. & Catto, J. W. Global epigenetic profiling in bladder cancer. Epigenomics 3, 35–45 (2011).
  Article CAS PubMed Google Scholar
• Sanchez-Carbayo, M. Hypermethylation in bladder cancer: biological pathways and translational applications. Tumour Biol. 33, 347–361 (2012). This is a comprehensive review of the extensive literature on DNA hypermethylation in bladder cancer.
  Article CAS PubMed Google Scholar
• Hoffman, A. M. & Cairns, P. Epigenetics of kidney cancer and bladder cancer. Epigenomics 3, 19–34 (2011).
  Article CAS PubMed Google Scholar
• Kandimalla, R. et al. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. Eur. Urol. 61, 1245–1256 (2012).
  Article CAS PubMed Google Scholar
• Marsit, C. J. et al. Identification of methylated genes associated with aggressive bladder cancer. PLoS ONE 5, e12334 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Reinert, T. et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin. Cancer Res. 17, 5582–5592 (2011).
  Article CAS PubMed Google Scholar
• Wolff, E. M. et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res. 70, 8169–8178 (2010). This genome-wide methylation study of normal urothelium and tumours of all grades and stages found distinct patterns of hypomethylation in NMIBCs and widespread promoter hypermethylation in invasive tumours.
  Article CAS PubMed PubMed Central Google Scholar
• Lauss, M. et al. DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. Epigenetics 7, 858–867 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Hovestadt, V. et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 510, 537–541 (2014).
  Article CAS PubMed Google Scholar
• Dudziec, E., Gogol-Doring, A., Cookson, V., Chen, W. & Catto, J. Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells. PLoS ONE 7, e32750 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Vallot, C. et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J. Natl Cancer Inst. 103, 47–60 (2011).
  Article CAS PubMed Google Scholar
• Wild, P. J. et al. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. Cancer Epidemiol. Biomarkers Prev. 18, 1798–1806 (2009).
  Article CAS PubMed Google Scholar
• Zuiverloon, T. C. et al. Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project. J. Urol. 189, 1945–1951 (2012). This study assesses combinations of urine biomarkers for detection and surveillance of bladder cancer in a large group of patients.
  Article CAS PubMed Google Scholar
• Zuiverloon, T. C. et al. Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay. J. Urol. 186, 707–712 (2011).
  Article CAS PubMed Google Scholar
• Chung, W. et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol. Biomarkers Prev. 20, 1483–1491 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Zuiverloon, T. C. et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int. 109, 941–948 (2012).
  Article CAS PubMed Google Scholar
• Renard, I. et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur. Urol. 58, 96–104 (2010).
  Article CAS PubMed Google Scholar
• Kandimalla, R. et al. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine. Clin. Cancer Res. 19, 4760–4769 (2013).
  Article CAS PubMed Google Scholar
• Allory, Y. et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur. Urol. 65, 360–366 (2013). This study identifies TERT promoter mutations at high frequency in bladder tumours of all grades and stages, and reports their use as a urine biomarker. These mutations are the most common event identified in bladder cancer so far.
  Article CAS PubMed Google Scholar
• Hurst, C. D., Platt, F. M. & Knowles, M. A. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur. Urol. 65, 367–369 (2013).
  Article CAS PubMed Google Scholar
• Apodaca, G. The uroepithelium: not just a passive barrier. Traffic 5, 117–128 (2004).
  Article CAS PubMed Google Scholar
• Gaisa, N. T. et al. The human urothelium consists of multiple clonal units, each maintained by a stem cell. J. Pathol. 225, 163–171 (2011).
  Article CAS PubMed Google Scholar
• Ho, P. L., Kurtova, A. & Chan, K. S. Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nature Rev. Urol. 9, 583–594 (2012).
  Article CAS Google Scholar
• van der Horst, G., Bos, L. & van der Pluijm, G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol. Cancer Res. 10, 995–1009 (2012).
  Article CAS PubMed Google Scholar
• He, X. et al. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells 27, 1487–1495 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Chan, K. S. et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl Acad. Sci. USA 106, 14016–14021 (2009).
  Article PubMed PubMed Central Google Scholar
• Kurtova, A. et al. Blocking PGE2-induced tumor repopulation abrogates bladder cancer chemoresistance. Nature http://dx.doi.org/10.1038/nature14034 (2014).
• Volkmer, J. P. et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc. Natl Acad. Sci. USA 109, 2078–2083 (2012). This study identifies tumour-initiating cells from bladder tumours of different grades and stages. A key finding is that tumour-initiating cells from aggressive tumours showed a basal phenotype, whereas those from non-invasive tumours had features of more differentiated cells, suggesting a non-basal derivation.
  Article PubMed PubMed Central Google Scholar
• Van Batavia, J. et al. Bladder cancers arise from distinct urothelial sub-populations. Nature Cell Biol. 16, 982–991 (2014).
  Article CAS PubMed Google Scholar
• Junker, K. et al. Analysis of genetic alterations in normal bladder urothelium. Urology 62, 1134–1138 (2003).
  Article PubMed Google Scholar
• Obermann, E. C. et al. Fluorescence in situ hybridization detects frequent chromosome 9 deletions and aneuploidy in histologically normal urothelium of bladder cancer patients. Oncol. Rep. 11, 745–751 (2004).
  CAS PubMed Google Scholar
• Chow, N. H. et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int. J. Cancer 89, 514–518 (2000).
  Article CAS PubMed Google Scholar
• Hartmann, A. et al. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am. J. Pathol. 154, 721–727 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• van Oers, J. M. M. et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int. J. Cancer 119, 1212–1215 (2006).
  Article CAS PubMed Google Scholar
• Hartmann, A. et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 62, 809–818 (2002).
  CAS PubMed Google Scholar
• Spruck, C. H. 3rd. et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54, 784–788 (1994).
  CAS PubMed Google Scholar
• Hopman, A. H. et al. Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. Am. J. Pathol. 161, 1119–1125 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Rosin, M. P., Cairns, P., Epstein, J. I., Schoenberg, M. P. & Sidransky, D. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res. 55, 5213–5216 (1995).
  CAS PubMed Google Scholar
• Zieger, K., Marcussen, N., Borre, M., Ørntoft, T. F. & Dyrskjøt, L. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. Int. J. Cancer 125, 2095–2103 (2009).
  Article CAS PubMed Google Scholar
• Czerniak, B. et al. Genetic modeling of human urinary bladder carcinogenesis. Genes Chromosomes Cancer 27, 392–402 (2000).
  Article CAS PubMed Google Scholar
• Gallucci, M. et al. Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters. J. Clin. Pathol. 58, 367–371 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, S. et al. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc. Natl Acad. Sci. USA 104, 13732–13737 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Stoehr, R. et al. Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones. Lab Invest. 82, 1553–1561 (2002).
  Article CAS PubMed Google Scholar
• Majewski, T. et al. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest. 88, 694–721 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hafner, C. et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 20, 4910–4915 (2001).
  Article CAS PubMed Google Scholar
• Cheng, L. et al. Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer 94, 104–110 (2002).
  Article PubMed Google Scholar
• Habuchi, T. Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications. Int. J. Urol. 12, 709–716 (2005).
  Article CAS PubMed Google Scholar
• Takahashi, T. et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res. 58, 5835–5841 (1998).
  CAS PubMed Google Scholar
• Kawanishi, H. et al. High throughput comparative genomic hybridization array analysis of multifocal urothelial cancers. Cancer Sci. 97, 746–752 (2006).
  Article CAS PubMed Google Scholar
• Kawanishi, H. et al. Genetic analysis of multifocal superficial urothelial cancers by array-based comparative genomic hybridisation. Br. J. Cancer 97, 260–266 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• van Tilborg, A. A. et al. Molecular evolution of multiple recurrent cancers of the bladder. Hum. Mol. Genet. 9, 2973–2980 (2000).
  Article CAS PubMed Google Scholar
• Letouzé, E., Allory, Y., Bollet, M. A., Radvanyi, F. & Guyon, F. Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. Genome Biol. 11, R76 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Borhan, A. et al. Grade progression and regression in recurrent urothelial cancer. J. Urol. 169, 2106–2109 (2003).
  Article CAS PubMed Google Scholar
• Lamouille, S., Subramanyam, D., Blelloch, R. & Derynck, R. Regulation of epithelial–mesenchymal and mesenchymal–epithelial transitions by microRNAs. Curr. Opin. Cell Biol. 25, 200–207 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Wiklund, E. D. et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int. J. Cancer 128, 1327–1334 (2011).
  Article CAS PubMed Google Scholar
• Adam, L. et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 15, 5060–5072 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• De Medina, S. G. et al. Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas. Oncogene 18, 5722–5726 (1999).
  Article CAS PubMed Google Scholar
• Chaffer, C. L. et al. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res. 66, 11271–11278 (2006).
  Article CAS PubMed Google Scholar
• Hu, H. et al. A novel role of Id-1 in regulation of epithelial-to-mesenchymal transition in bladder cancer. Urol. Oncol. 31, 1242–1253 (2012).
  Article CAS PubMed Google Scholar
• Luo, M. et al. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett. 333, 213–221 (2013).
  Article CAS PubMed Google Scholar
• Fan, Y. et al. TGF-β -induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin. Cancer Res. 20, 1531–1541 (2014).
  Article CAS PubMed Google Scholar
• Karni-Schmidt, O. et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am. J. Pathol. 178, 1350–1360 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Tran, M. N. et al. The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of miR-205. J. Biol. Chem. 288, 3275–3288 (2013).
  Article CAS PubMed Google Scholar
• Choi, W. et al. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS ONE 7, e30206 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl Acad. Sci. USA 111, 3110–3115 (2014). This is one of three recent gene expression profiling studies of MIBC that define major basal and luminal expression subtypes. (See also references 37 and 194).
  Article CAS PubMed PubMed Central Google Scholar
• Griner, E. M. & Theodorescu, D. The faces and friends of RhoGDI2. Cancer Metastasis Rev. 31, 519–528 (2012).
  Article CAS PubMed Google Scholar
• Wu, Y. et al. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc. Natl Acad. Sci. 106, 5807–5812 (2009).
  Article PubMed PubMed Central Google Scholar
• Fanning, P. et al. Elevated expression of pp60c–src in low grade human bladder carcinoma. Cancer Res. 52, 1457–1462 (1992).
  CAS PubMed Google Scholar
• Qayyum, T. et al. The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. Br. J. Cancer 106, 1187–1195 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Said, N., Sanchez-Carbayo, M., Smith, S. C. & Theodorescu, D. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J. Clin. Invest. 122, 1503–1518 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Said, N. & Theodorescu, D. RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment. Oncoimmunology 1, 1175–1177 (2012).
  Article PubMed PubMed Central Google Scholar
• Said, N., Frierson, H. F., Sanchez-Carbayo, M., Brekken, R. A. & Theodorescu, D. Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J. Clin. Invest. 123, 751–766 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Yuan, X. et al. ATF3 suppresses metastasis of bladder cancer by regulating gelsolin-mediated remodeling of the actin cytoskeleton. Cancer Res. 73, 3625–3637 (2013).
  Article CAS PubMed Google Scholar
• Smith, S. C. & Theodorescu, D. The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target. Urol. Oncol. 27, 42–47 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Saito, R. et al. Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer. Oncogene 32, 894–902 (2013).
  Article CAS PubMed Google Scholar
• Overdevest, J. B. et al. CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res. 71, 3802–3811 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Overdevest, J. B. et al. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc. Natl Acad. Sci. USA 109, E3588–E3596 (2012).
  Article PubMed PubMed Central Google Scholar
• Blaveri, E. et al. Bladder cancer outcome and subtype classification by gene expression. Clin. Cancer Res. 11, 4044–4055 (2005).
  Article CAS PubMed Google Scholar
• Dyrskjot, L. et al. Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR. Br. J. Cancer 107, 1392–1398 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Dyrskjot, L. et al. Identifying distinct classes of bladder carcinoma using microarrays. Nature Genet. 33, 90–96 (2003).
  Article CAS PubMed Google Scholar
• Dyrskjot, L. et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin. Cancer Res. 13, 3545–3551 (2007).
  Article CAS PubMed Google Scholar
• Sanchez-Carbayo, M., Socci, N. D., Lozano, J., Saint, F. & Cordon-Cardo, C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24, 778–789 (2006).
  Article CAS PubMed Google Scholar
• Kim, W.-J. et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol. Cancer 9, 3 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Sjödahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377–3386 (2012). This study was the first to describe a molecular taxonomy for bladder cancer based on gene expression profiling of tumours of all stages and grades. Molecular subtypes traversing pathological classification and with distinct clinical outcomes are reported.
  Article CAS PubMed Google Scholar
• Sjödahl, G. et al. Toward a molecular pathologic classification of urothelial carcinoma. Am. J. Pathol. 183, 681–691 (2013).
  Article CAS PubMed Google Scholar
• Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152–165 (2014). This is one of three recent gene expression profiling studies of MIBC that define major basal and luminal expression subtypes. See also references 37 and 173. This study defines two luminal subtypes, one of which contains tumours that show resistance to cisplatin-based therapy.
  Article CAS PubMed PubMed Central Google Scholar
• Choi, W. et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nature Rev. Urol. 11, 400–410 (2014). This is a useful review of recent expression profiling studies that identifies overlap of clusters defined by different groups and highlights specific features of the subtypes defined.
  Article CAS Google Scholar
• Hoadley, K. A. et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929–944 (2014). This excellent pan-cancer study includes data on MIBC from a TCGA study and shows alignment of bladder tumours with squamous features with aggressive breast and ovarian cancers.
  Article CAS PubMed PubMed Central Google Scholar
• Aine, M., Liedberg, F., Sjodahl, G. & Hoglund, M. Re: David J., McConkey, Woonyoung Choi, Colin, P. N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.08.063 (2014).
• McConkey, D., Choi, W. & Dinney, C. Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjodahl & Mattias Hoglund's Letter to the Editor re: David, J. McConkey, Woonyoung Choi, Colin, P. N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.08.064 (2014).
• Rebouissou, S. et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci. Transl Med. 6, 244ra291 (2014).
  Article CAS Google Scholar
• Wilhelm-Benartzi, C. S. et al. DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer. Carcinogenesis 31, 1972–1976 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Lindgren, D. et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 70, 3463–3472 (2010).
  Article CAS PubMed Google Scholar